Adam H. Golden

Adam H. Golden

New York

Email adam.golden@​

Phone +1 212 918 3636

Fax +1 212 918 3100

Practice groupCorporate & Finance

Head of the Corporate practice in New York, Adam Golden advises life sciences companies on some of their most important transactions. Clients turn to Adam for his dual skillset, which combines his strengths as an M&A and corporate lawyer with those of an IP transactions lawyer. This enables him to represent pharmaceutical, biotech, and medical device companies in the full scope of transactions that are common to this sector.

Over his career, Adam has advised clients on M&A, license and collaboration deals, venture capital financings, and commercial transactions. Frequently, clients seek his advice on hybrid transactions such as M&A transactions with back-end milestone payments or contingent value rights, options to acquire companies or technology, and product divestitures. He also advises clients on the transition service, manufacturing and supply, and other operational agreements that often accompany these transactions.

Adam is recognized as a leading practitioner in Chambers Global, Chambers USA, Legal 500 US, Who's Who Legal, LMG Life Sciences, and IAM Patent 1000. In 2018, he was named M&A Attorney of the Year by LMG Life Sciences, and a Life Sciences MVP by Law360.

Awards and recognitions


Life Sciences: Corporate/Commercial (USA)
Chambers Global


Life Sciences: Corporate/Commercial (Nationwide)
Chambers USA


Healthcare: Life Sciences, Leading Lawyer
Legal 500 US


M&A/Corporate and Commercial: M&A: Large Deals ($1bn+)
Legal 500 US


Life Sciences Star - Finance & Transactional
LMG Life Sciences


Life Sciences - Transactional
Who's Who Legal


Corporate and M&A, Notable Practitioner


Pharmaceuticals and Life Sciences, Notable Practitioner

Education and admissions


J.D., New York University School of Law, 1990

A.B., Princeton University, 1986

Bar admissions and qualifications

New York


Representative experience

Ipsen on the sale to Fusion Pharmaceuticals of rights to a radiopharmaceutical being developed for oncology indications.

Gilead Sciences on its strategic collaboration with Tango Therapeutics, to develop and commercialize innovative targeted immuno-oncology treatments for cancer.

Novartis on its acquisition of Cadent Therapeutics, a clinical-stage neuroscience company.

Engrail Therapeutics on its acquisition of NeuroCycle Therapeutics, a company focused on sub-type selective GABA-A modulation.

Novartis on its acquisition of Vedere Bio, including a platform for AAV-based delivery of gene therapies and an optogenetics program.

Altavant Sciences on its acquisition of Onspira Therapeutics, a private drug development company focused on therapeutics for rare pulmonary diseases.

Bausch Health on its option to purchase the ophthalmology assets of Allegro Pharmaceuticals.

Novartis on its acquisition of IFM Tre for up to US$1.6bn and its option to acquire IFM Due for up to US$840m.

Celgene Corporation, on its US$9bn acquisition of Juno Therapeutics, a clinical-stage cell immunotherapy company.

Novartis, on its US$8.7bn acquisition of AveXis Inc., a clinical-stage gene therapy biotech company.

Celgene Corporation, on its acquisition of Impact Biomedicines for up to US$7bn, a clinical stage company developing fedratinib for myelofibrosis.

Chase Pharmaceuticals on its sale to Allergan for up to US$1bn.

Alcon Laboratories on its acquisitions of Encore Vision, RxSight, and Transcend Medical.

Kite, a Gilead company, in an up to US$3bn deal to access Sangamo Therapeutics' zinc finger nuclease technology.

Celgene on strategic collaborations and equity investments, including with Kyn Therapeutics, Ex Scientia, Obsidian Therapeutics, Jounce Therapeutics, and Skyhawk Therapeutics.

Gilead Sciences on its US$150m collaboration with Agenus to develop and commercialize novel immuno-oncology therapies.

Novartis on its collaboration with Cellular Biomedicine Group to support the introduction of the CAR-T cell therapy Kymriah® (tisagenlecleucel) in China.

Bausch Health on the sale of Dendreon Pharmaceuticals to the Sanpower Group Co., Ltd., one of the largest privately owned conglomerates in China.

Novartis on strategic collaborations with Sangamo Therapeutics, Surface Therapeutics, Xencor, and Homology Medicines.

Buyers and sellers of FDA priority review vouchers.

Loading data